| 1 |
34837219 | Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. | 2022 Jun |
2 |
| 2 |
33345848 | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. | 2021 Feb 15 |
2 |
| 3 |
33674391 | COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. | 2021 May |
4 |
| 4 |
34785211 | Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. | 2021 Dec 15 |
1 |
| 5 |
30447156 | Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. | 2019 Apr |
1 |
| 6 |
22391528 | In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. | 2012 Jun |
2 |
| 7 |
14729380 | Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. | 2004 Jan 19 |
1 |
| 8 |
10664060 | Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. | 2000 Jan |
1 |
| 9 |
945675 | [The ERG in chloroquine retinopathy (author's transl)]. | 1976 |
1 |
| 10 |
5226562 | Discussion: modifications of the ERG during chloroquine intoxications. | 1966 |
1 |